KDR and hepatocellular carcinoma: Grade 3 TRAEs occurred in 8 (40.0%) patients, which is comparable to that (36.0%) in the IMbrave150 trial (16), but apparently lower than that (74.7%) with camrelizumab, an anti–PD-1 monoclonal antibody, plus apatinib, a VEGFR2 inhibitor, as first-line treatment for advanced HCC in the phase II RESCUE trial (26).